Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all‑oral, interferon‑free regimen

Antiviral Therapy

Volumn 23, Issue 3, 2018, Pages 211-217

  Chevaliez, Stéphane ^a   Feld, Jordan ^b   Cheng, Kevin ^c   Wedemeyer, Heiner ^d   Sarrazin, Christoph ^e   Maasoumy, Benjamin ^d   Herman, Christine ^c   Hackett, John ^c   Cohen, Daniel ^f   Dawson, George ^c   Pawlotsky, Jean Michel ^a   Cloherty, Gavin ^c  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITY OF TORONTO   (Canada)

^c ABBOTT LABORATORIES   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA; ANTIVIRUS AGENT; VIRUS ANTIGEN;

ADULT; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HUMAN; PRIORITY JOURNAL; RNA ANALYSIS; SUSTAINED VIROLOGIC RESPONSE; COMBINATION DRUG THERAPY; DISEASE MANAGEMENT; HEPACIVIRUS; IMMUNOASSAY; IMMUNOLOGY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOASSAY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85049575818     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3042     Document Type: Article

References (27)

1. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61 Suppl:S45–S57.
2. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26:401–412.
3. The Global Burden of Hepatitis C Working Group. The global burden of hepatitis C. J Clin Pharmacol 2004; 44:20–29.
4. Zeuzem S, Jacobsen IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1604–1614.
5. Hezode C, Marcellin P, Pol S, et al. Results from the Phase 2 PEARL-I study: interferon-free regimens of ABT-450/R + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. 49th EASL. 9–13 April 2014, London, UK. Oral abstract O58.
6. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594–1603.
7. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973–1982.
8. Ferenci P, Bernstein D, Lalezari J, et al. PEARL III: 12 weeks of ABT-450/R/267 + ABT-333 achieved SVR in >99% of treatment-naive HCV genotype 1b-infected adults without or without ribavirin. 49th EASL. 9–13 April 2014, London, UK. Abstract P1299.
9. Morota K, Fujinami R, Kinukawa H, et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 2009; 157:8–14.
10. Mederacke I, Wedemeyer H, Ciesek S, et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009; 46:210–215.
11. Ross RS, Viazov S, Salloum S, Hilgard P, Gerken G, Roggendorf M. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 2010; 48:1161–1168.
12. Medici MC, Furlini G, Rodella A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011; 51:264–269.
13. Heidrich B, Pischke S, Helfritz FA, et al. Hepatitis C virus core antigen testing in liver and kidney transplant recipients. J Viral Hepat 2014; 21:769–779.
14. Ottiger C, Gygli N, Huber AR. Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J Clin Virol 2013; 58:535–540.
15. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36:211–218.
16. Chevaliez S, Soulier A, Poiteau L, Bouvier-Alias M, Pawlotsky JM. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clin Virol 2014; 61:145–148.
17. Kesli R, Polat H, Terzi Y, Kurtoglu MG, Uyar Y. Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results. J Clin Microbiol 2011; 49:4089–4093.
18. Mederacke I, Potthoff A, Meyer-Olson D, et al. HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. J Clin Virol 2012; 53:110–115.
19. Ergünay K, Sener B, Alp A, Karakaya J, Hasçelik G. Utility of commercial quantitative hepatitis C core antigen assay in a diagnostic laboratory setting. Diagn Microbiol Infect Dis 2011; 70:486–491.
20. Buket CA, Ayşe A, Selçuk K, Süleyman Ö, Emel SÇ. Comparison of HCV core antigen and anti-HCV with HCV RNA results. Afr Health Sci 2014; 14:816–820.
21. Vermehren J, Susser S, Berger A, et al. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol 2012; 55:17–22.
22. Hadziyannis E, Minopetrou M, Georgiou A, Spanou F, Koskinas J. Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated assays. Ann Gastroenterol 2013; 26:146–149.
23. Kadkhoda K, Smart G. HCV antigen testing for the diagnosis of hepatitis C infection: a cost-efficient algorithm. Clin Lab 2014; 60:677–680.
24. Park Y, Lee JH, Kim BS, Kim DY, Han KH, Kim HS. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010; 48:2253–2256.
25. Chevaliez S, Soulier A, Poiteau L, Bouvier-Alias M, Pawlotsky JM. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. J Clin Virol 2014; 61:145–148.
26. Tedder RS, Tuke P, Wallis N, Wright M, Nicholson L, Grant PR. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response. J Viral Hepat 2013; 20:65–71.
27. Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct acting antiviral therapy. Clin Infect Dis 2015; 60:1743–1751.